CVS re­sumes cov­er­age of block­buster blood thin­ner af­ter price drop fol­lows Jan­u­ary ex­clu­sion

Fol­low­ing some back­lash from the Amer­i­can Col­lege of Car­di­ol­o­gy and pa­tients, Bris­tol My­ers Squibb and Pfiz­er low­ered the price of their block­buster blood thin­ner Eliquis, thus en­sur­ing that CVS Care­mark would cov­er the drug af­ter 6 months of it be­ing off the ma­jor PBM’s for­mu­la­ry.

“Be­cause we se­cured low­er net costs for pa­tients from ne­go­ti­a­tions with the drug man­u­fac­tur­er, Eliquis will be added back to our tem­plate for­mu­la­ries for the com­mer­cial seg­ment ef­fec­tive Ju­ly 1, 2022, and pa­tient choic­es will be ex­pand­ed,” CVS Health said in an emailed state­ment. “An­ti-co­ag­u­lant ther­a­pies are among the non-spe­cial­ty prod­ucts where we are see­ing the fastest cost in­creas­es from drug man­u­fac­tur­ers and we will con­tin­ue to push back on un­war­rant­ed price in­creas­es.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER